Zobrazeno 1 - 10
of 206
pro vyhledávání: '"Jérôme, Fayette"'
Autor:
Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, Caroline Hoffmann, Gilles Dolivet, Olivier Malard, Jérôme Fayette, Olivier Capitain, Sébastien Vergez, Lionel Geoffrois, Frédéric Rolland, Philippe Zrounba, Laurent Laccourreye, Esma Saada-Bouzid, Nicolas Aide, Valérie Bénavent, Jerzy Klijianenko, Constance Lamy, Elodie Girard, Sophie Vacher, Julien Masliah-Planchon, Leanne de Koning, Vincent Puard, Edith Borcoman, Marta Jimenez, Ivan Bièche, Jocelyn Gal, Christophe Le Tourneau
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase inhi
Externí odkaz:
https://doaj.org/article/71b235740be44697822692560686e4ae
Autor:
Juliette Dessemon, Olivia Perol, Cécile Chauvel, Hugo Noelle, Thomas Coudon, Lény Grassot, Nicolas Foray, Elodie Belladame, Jérôme Fayette, Françoise Fournie, Aurélie Swalduz, Eve-Marie Neidhart, Pierre Saintigny, Mayeul Tabutin, Maxime Boussageon, Frédéric Gomez, Virginie Avrillon, Maurice Perol, Barbara Charbotel, Béatrice Fervers
Publikováno v:
Frontiers in Public Health, Vol 11 (2024)
IntroductionResidential exposure is estimated to be responsible for nearly 10% of lung cancers in 2015 in France, making it the second leading cause, after tobacco. The Auvergne-Rhône-Alpes region, in the southwest of France, is particularly affecte
Externí odkaz:
https://doaj.org/article/59eed2ed0592472bacd7aa9539ba0b7b
Autor:
Bao-Tram Thi Tran, Aurore Gelin, Sylvère Durand, Matthieu Texier, Amaury Daste, Clémence Toullec, Karim Benihoud, Ingrid Breuskin, Philippe Gorphe, Florence Garic, Catherine Brenner, Christophe Le Tourneau, Jérôme Fayette, Toshiro Niki, Muriel David, Pierre Busson, Caroline Even
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTExtra-cellular galectins 1, 3 and 9 (gal-1, −3 and −9) are known to act as soluble immunosuppressive agents in various malignancies. Previous publications have suggested that their expression is dependent on the metabolic status of produc
Externí odkaz:
https://doaj.org/article/719766cfc1884b85a06769ebea03df1c
Autor:
Coauthor(s) Thibault Gauduchon, Cécile Dalban, Zrounba Philippe, Séverine Racadot, Sylvie Chabaud, Emile Reyt, Marc Poupart, Jean Michel Prades, Michael Burgy, Dominique Cellier, Philippe Ceruse, Jacques Leval, Philippe Muller, Patrick Manipoud, Isabelle Ray-Coquard, Jérôme Fayette
Publikováno v:
Oral Oncology Reports, Vol 6, Iss , Pp 100042- (2023)
Background: The initial curative standard treatment for LAHNSCC is exclusive CRT (chemoradiotherapy) or surgery ( ± CRT) which give similar results in term of PFS and OS. Indication depends on several factors including regional expertise and a
Externí odkaz:
https://doaj.org/article/dc089b916e9e46d08a63c97c9235e8f6
Autor:
Jean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, Maxime Boussageon, Lucas Michon, Jebrane Bouaoud, Dorssafe Fekiri, Marie Robert, Kim-Arthur Baffert, Geneviève Hervé, Pauline Quilhot, Valéry Attignon, Angélique Girod, André Chaine, Mourad Benassarou, Philippe Zrounba, Christophe Caux, François Ghiringhelli, Sylvie Lantuejoul, Carole Crozes, Isabelle Brochériou, Maurice Pérol, Jérôme Fayette, Chloé Bertolus, Pierre Saintigny
Publikováno v:
Data in Brief, Vol 44, Iss , Pp 108556- (2022)
Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. In this co
Externí odkaz:
https://doaj.org/article/dc4e546ef4f94d60bcf8550d81ded5eb
Autor:
Thomas Chevalier, Amaury Daste, Esmaa Saada‐Bouzid, Anderson Loundou, Florent Peyraud, Tiphaine Lambert, Christophe Le Tourneau, Frédéric Peyrade, Charlotte Dupuis, Marc Alfonsi, Jérôme Fayette, Juliette Reure, Florence Huguet, Nicolas Fakhry, Clémence Toullec, Sébastien Salas
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3952-3963 (2021)
Abstract BACKGROUND Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients’ ou
Externí odkaz:
https://doaj.org/article/5723658a1a9f4460a7ff6b0ae310d7cc
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer worldwide. More than half of HNSCC patients experience locoregional or distant relapse to treatment despite aggressive multimodal therapeutic approaches that include surg
Externí odkaz:
https://doaj.org/article/208f4db2033f46b8a7232cb7ebb375ce
Autor:
Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de los Reyes, Craig Barker, Jessica Whiteley, Robert Haddad, Lisa Licitra, Robert Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Ricard Mesía
Publikováno v:
Clinical Cancer Research. 29:2066-2074
Purpose: Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::911eb9ff1492de58a03ea819de5f5d9a
https://doi.org/10.1158/1078-0432.ccr-22-2765
https://doi.org/10.1158/1078-0432.ccr-22-2765
Autor:
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac, Nicolas Benoit, Pierre Bombaron, Denis Moro-Sibilot, Clarisse Audigier-Valette, Bernard Asselain, Thomas Egenod, Audrey Rabeau, Jérôme Fayette, Myriam Locatelli Sanchez, Jean-Luc Labourey, Virginie Westeel, Pauline Lamoureux, François-Emery Cotte, Victoria Allan, Melinda Daumont, Juliette Dumanoir, Dorothée Reynaud, Christophe Yannick Calvet, Nicolas Ozan, Maurice Pérol
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Externí odkaz:
https://doaj.org/article/213acd05a7a34a719db64a6b6903acd4
Autor:
Jean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, Maxime Boussageon, Lucas Michon, Jebrane Bouaoud, Dorssafe Fekiri, Marie Robert, Kim-Arthur Baffert, Geneviève Hervé, Pauline Quilhot, Valéry Attignon, Angélique Girod, André Chaine, Mourad Benassarou, Philippe Zrounba, Christophe Caux, François Ghiringhelli, Sylvie Lantuejoul, Carole Crozes, Isabelle Brochériou, Maurice Pérol, Jérôme Fayette, Chloé Bertolus, Pierre Saintigny
Publikováno v:
European Journal of Cancer. 174:287-298
Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd48498ad82f20b2b7800fef1c60d54
https://doi.org/10.1016/j.ejca.2022.06.034
https://doi.org/10.1016/j.ejca.2022.06.034